<DOC>
	<DOCNO>NCT01764087</DOCNO>
	<brief_summary>The primary objective study determine maximum tolerate dose ( MTD ) KX2-391 Combination paclitaxel Phase I , evaluate efficacy KX2-391 combination paclitaxel patient diagnose gastric breast cancer , respectively Phase II .</brief_summary>
	<brief_title>A Study KX2-391 With Paclitaxel Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Phase I Portion : Diagnosis solid tumor histopathological examination cytological examination standard care available conventional treatment modality therapeutic effect time enter study Phase II Portion : Diagnosis advanced/metastatic/recurrent stomach cancer breast cancer histopathological examination cytological examination standard care available conventional treatment modality therapeutic effect time enter study Subjects stomach cancer without prior taxane therapy Subjects breast cancer prior taxane therapy ( Optional ) Providing exploratory biomarker inform consent form obtain archival tumor tissue and/or new tumor biopsy sample Common : 1 . Based clinical screening , ① If radiotherapy give , least 4 week pass last treatment date patient recover toxicity ( However , limited regional radiotherapy , least 2 week last treatment date ) ② If hormonal therapy give , least 2 week pass last treatment date patient recover toxicity . ③ If chemotherapy give , least 3 week pass last treatment date patient recover toxicity ( However , nitrosourea mitomycin , least 6 week ) 2 . Aged ≥ 20 year 3 . ECOG ( Eastern Cooperative Oncology Group ) ≤ 2 4 . Life expectancy ≥ 12 week 5 . Should meet following , ① Bone marrow function ANC ( Absolute Neutrophil Count ) ≥ 1.5 X 109/L , PLT ( Platelet Count ) ≥ 100 X 109/L , Hemoglobin ≥ 9.0 g/dl ( In case hemoglobin &lt; 9.0 g/dl , patient enrol value reverse ≥ 9.0 g/dl . ) ② Kidney function Creatinine Clearance &gt; 50 ml/min Serum Clearance ≤ 1.5 mg/dl ③ Liver function AST ( Aspartate Aminotransferase ) /ALT ( Alanine Aminotransferase ) /ALP ( Alkaline Phosphatase ) ≤ 3.0 X UNL Total bilirubin ≤ 2.0 mg/dl ( With bone metastasis , ALP ≤ 5.0 X UNL ) 6 . At least one measurable lesion length long diameter ≥ 10 mm spiral CT multidetector CT ≥ 20 mm conventional CT 7 . Subjects voluntarily consent participate study sign write informed consent form 1 . Uncontrolled central nervous system metastasis 2 . Malignant ascites require surgical treatment 3 . Subjects blood malignancy include leukemia ; receive receive bone marrow transplantation 4 . Severe concurrent disease follow , ① History unstable angina , heart failure , atrial ventricular arrhythmia require pharmacological treatment , receive treatment myocardial infarction within 6 month ( however , may include judgment investigator medically control ) , heart failure Class III IV New York Heart Association Classes , leave ventricular ejection fraction &lt; 40 % ② Receiving therapeutic dose administration coumarintype anticoagulant ( however , 2 mg daily permit line open ) ③ Uncontrolled diabetes ( fast plasma glucose &gt; 2.0 X UNL ) , severe hypertension , thyroid disorder active infectious disease ④ Psychiatric neurological history include dementia epilepsy may threaten compliance protocol ⑤ A condition allow oral application tablet formulation , clinically significant gastrointestinal abnormality may interfere take , pass absorption study drug 5 . Using disallowed concomitant medication ( strong CYP3A4 ( Cytochrome P450 3A4 ) inhibitor inducer ) ( When patient use disallow concomitant medication , washout 1 week medication date require ) 6 . Received investigational product within 4 week prior administration study drug 7 . Pregnant breastfeed woman ( however , woman 12 month natural ( spontaneous ) amenorrhea surgical bilateral oophorectomy ( alone hysterectomy ) least 6 week ago , appropriate clinical profile ( e.g. , appropriate age , history vasomotor symptom ) , consider woman postmenopausal nonchildbearing potential . In case oophorectomy alone , woman consider nonchildbearing potential reproductive condition confirm followup hormone level assessment ) 8 . History hypersensitivity paclitaxel , compound similar chemical structure , cremophor ( polyoxyethylated castor oil ) ingredient 9 . Neuropathy grade ≥ 3 base clinical screen 10 . Known history hepatitis B C known history HIV serum positive 11 . Others unable participate study judgment investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Stomach Neoplasms</keyword>
	<keyword>Breast Neoplasms</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Tubulin Modulators</keyword>
	<keyword>Antimitotic Agents</keyword>
	<keyword>Protein Kinase Inhibitors</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>Pharmacologic Actions</keyword>
</DOC>